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Abstract 
The non-genomic mechanisms by which glucocorticoids modulate β2 agonist-induced-
bronchodilation remain elusive. Our studies aimed to elucidate mechanisms mediating 
the beneficial effects of glucocorticoids on agonist-induced bronchodilation.  Utilizing 
human precision cut lung slices (hPCLS), we measured bronchodilation to formoterol, 
prostaglandin E2 (PGE2), cholera toxin (CTX) or forskolin in the presence and absence of 
budesonide.  Using cultured human airway smooth muscle (HASM), intracellular cAMP 
was measured in live cells following exposure to formoterol, PGE2, or forskolin in the 
presence or absence of budesonide.  We showed that simultaneous budesonide 
administration amplified formoterol-induced bronchodilation and attenuated agonist-
induced phosphorylation of myosin light chain, a necessary signaling event mediating 
force generation. In parallel studies, cAMP levels were augmented by simultaneous 
exposure of HASM cells to formoterol and budesonide. Budesonide, fluticasone and 
prednisone alone rapidly increased cAMP levels, but steroids alone had little effect on 
bronchodilation in hPCLS. Bronchodilation induced by PGE2, CTX or forskolin was also 
augmented by simultaneous exposure to budesonide in hPCLS. Furthermore, HASM 
cells expressed membrane-bound glucocorticoid receptors that failed to translocate with 
glucocorticoid stimulation, and that potentially mediated the rapid effects of steroids on β2 
agonist-induced bronchodilation.  Knockdown of glucocorticoid receptor α had little effect 
on budesonide-induced and steroid-dependent augmentation of formoterol-induced 
cAMP generation in HASM.  Collectively, these studies suggest that glucocorticoids 
amplify cAMP-dependent bronchodilation by directly increasing cAMP levels. These 
studies identify a molecular mechanism by which the combination of glucocorticoids and 
β2 agonists may augment bronchodilation in diseases such as asthma or chronic 
obstructive pulmonary disease. 
  
Introduction 
Combination therapy including an inhaled glucocorticoid and a long-acting β2 
agonist represents a cornerstone in the management of airways disease including asthma 
and chronic obstructive pulmonary disease. Conceptually, combined use of an anti-
inflammatory agent with a bronchodilator improves medication adherence as compared 
to using each drug separately (1-3). Use of an inhaled corticosteroid (ICS) with a long-
acting β2 agonist (LABA) as rescue and maintenance therapy appears more effective than 
using an ICS or SABA alone or using an ICS/LABA for maintenance (4-10). Evidence 
now suggests, apart from enhanced adherence, combination therapy augments efficacy 
of either drug alone (11).  We posit that this effect is mediated by a rapid, non-genomic 
effect of glucocorticoids. To date, the molecular mechanisms by which non-genomic 
effects of glucocorticoids modulate bronchodilation remain unknown. (11). 
Glucocorticoids primarily mediate their effects by activating the glucocorticoid 
receptor (GR). In this canonical signaling, the GR resides in the cytoplasm in its inactive 
state and, upon ligand activation, translocates to the cell nucleus to interact with 
glucocorticoid response elements (GREs) and produce genomic effects altering protein 
expression. Recent evidence has emerged to suggest that glucocorticoids manifest rapid 
non-genomic actions on several signaling processes (11). These non-canonical, non-
genomic effects of glucocorticoids appear to involve non-specific interactions with the cell 
membrane and/or specific interactions with cytosolic GRs (cGR) or membrane-bound 
GRs (mGR). The rapid non-genomic effects appear to, at least in part, be mediated 
through a putative mGR (11).  
Several studies have reported an interaction of mGR with other membrane 
receptors, particularly G protein-coupled receptors (GPCR) (12).  Involvement of mGR 
and GPCR-dependent mechanisms in the rapid effect (~ 1 min) of corticosterone on 
NMDA-evoked currents in hippocampal neurons was demonstrated (12), suggesting that 
mGR may couple to multiple G proteins, including Gαs and Gαq/11. Other studies suggest 
that mGR directly activates downstream intracellular signaling pathways. Corticosterone 
acted via mGR to rapidly elicit PKC-dependent activation of ERK1/2 MAPK pathway in 
PC12 cells (13). Interestingly, proteomic analysis of CCRF-CEM cells identified 128 
proteins that were differentially regulated by activation of mGR using BSA-conjugated 
cortisol briefly (5 and 15 min) (14). These actions were unique to mGR, as no activation 
of cGR target genes (e.g. GILZ) were observed. Signal pathway analysis now provides 
evidence that mGR is involved in numerous pathways that are also regulated by 
glucocorticoids through cGR, suggesting that mGRs trigger early priming events, 
ultimately facilitating slower genomic activation by glucocorticoids (14).  
Our study identifies a molecular mechanism by which glucocorticoids acutely 
amplify β2 agonist-induced bronchodilation. By rapidly stimulating cAMP production, 
glucocorticoids augment the primary second messenger signal of β2 agonists and other 
bronchodilators. Ultimately, identification of plasma membrane components through 
which glucocorticoids impact cAMP signaling and bronchodilation may provide novel 
therapeutic targets for airways diseases, an area that has seen little innovation in the past 
45 years. 
 
Methods 
 
Reagents 
Reagents were purchased from the following vendors: formoterol, forskolin, 
carbachol, and TNFα (Sigma Aldrich, St. Louis, MO); budesonide (AstraZeneca); cell 
culture media and components (ThermoFisher, Waltham, MA); fetal bovine serum 
(Atlanta Biologicals, Flowery Branch, GA); GR antibody (Santa Cruz, Dallas, TX); β-actin 
antibody (Sigma Aldrich, St. Louis, MO); phosphorylated GRα (Cell Signaling 
Technology, Danvers, MA);  rabbit and mouse secondary antibodies for immunoblotting 
(LiCor, Lincoln, NE);  GRα targeted siRNA (Ambion, Austin, TX); non-targeting siRNA 
(Dharmacon, Lafayette, CO); HiPerFect transfection reagent (Qiagen, Germantown, MD); 
single analyte ELISA kits for IL-6, RANTES, and IL-8 (R&D Systems, Minneapolis, MN). 
 
hPCLS generation and bronchodilation assays 
Human precision cut lung slices (hPCLS) were prepared as previously described 
(15). Briefly, whole human lungs from non-asthma donors were dissected and inflated 
using 2% (wt/vol) low melting point agarose. Once the agarose set, the lobe was 
sectioned, and cores of 8-mm diameter were made. Cores containing small airways by 
visual inspection were sliced at a thickness of 350 μm (Precisionary Instruments VF300 
Vibratome, Greenville, NC) and collected in wells containing supplemented Ham’s F-12 
medium. To study bronchodilation, small airways contained within hPCLS were 
contracted with carbachol (CCh, 10-5 M), and then bronchodilated to formoterol (10-12 – 
10-6 M), budesonide (10-12 – 10-5 M), forskolin (10-12 – 10-5 M), PGE2 (10-10 – 10-5 M), or 
cholera toxin (0.01-100 µg/ml) ± budesonide (10-5 M, simultaneous administration). 
Human lung tissue samples were commercially obtained from anonymous donors 
(National Disease Research Interchange, Philadelphia, PA or the International Institute 
for the Advancement of Medicine, Edison, NJ), and are therefore exempt from IRB 
(Institutional Review Board) approval. Although these samples have demographic 
information, there is no information linking the subject’s identification to the tissue.  
Integrated area under the curve (AUC - % dilation/bronchodilator dose) was calculated 
from the dose response curves and was plotted along with maximal bronchodilation 
achieved over the entire dose response curve. 
 
Human airway smooth muscle (HASM) cells 
HASM cells were derived from tracheas obtained from non-asthma donor lungs 
that hPCLS were derived from. HASM cell culture was performed as described previously 
(16). Briefly, the cells were cultured in Ham’s F-12 medium supplemented with 10% FBS, 
100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2.5 mg/ml amphotericin B, and this 
medium was replaced every 72 hr. HASM cells in subculture during passages 1–5 were 
used, because these cells retain expression of native contractile proteins, as 
demonstrated by immunocytochemical staining for smooth muscle actin and myosin (17).  
 
cAMP assays 
For kinetic measurement of cAMP production in live cells, subconfluent HASM 
cells were plated in black-walled, clear flat bottom 96-well plates with HASM media, 
BacMam virus expressing the green cAMP difference detector in situ (cADDis) cAMP 
sensor (Montana Molecular, Bozeman, MT), and 1 μM trichostatin-A (Sigma Aldrich, St. 
Louis, MO) per well and grown overnight. Media was aspirated and replaced with PBS 
without calcium or magnesium, then the plate was covered and incubated at room 
temperature. Cell fluorescence was read from the plate bottom using excitation/emission 
wavelengths of 494 nm and 522 nm, respectively, using a SpectraMax M5 plate reader 
(Molecular Devices, Sunnyvale, CA). A kinetic read (5 min) on unstimulated cells was 
performed to determine variability in each well’s fluorescence (≤5%). Cells were 
stimulated with agonist and fluorescence changes were read at 30 second intervals for 
30 min.  
 
Cell surface biotinylation 
 Cell surface protein biotinylation was carried out according to manufacturer’s 
protocols (Pierce Biotechnology, Rockford, IL). Cells were grown to 90-95% confluence, 
incubated with a biotin solution, then scraped and lysed. Lysates were incubated with 
NeutrAvidin beads, then bound proteins eluted off. Eluates were assessed for 
glucocorticoid receptor, using epidermal growth factor receptor (EGFR; Cell Signaling 
Technology, Danvers, MA) as a positive control for cell surface biotinylation. Remaining 
cell lysates were examined for expression of GAPDH (Millipore, Burlington, MA) and 
COXIV (Cell Signaling Technology, Danvers, MA) as measures of intracellular/cytosolic 
proteins. 
 
Immunohistochemistry 
HASM cells were grown in chamber slides until confluent, then serum starved for 
18 hr. Cells were then fixed with 1% paraformaldehyde, washed, then blocked with 1% 
BSA/PBS solution containing 10% FcR block (Miltenyi Biotec, Auburn, CA). Cells were 
stained with a GR antibody (rabbit, Santa Cruz Biotechnology, Dallas, TX) in 1% 
BSA/PBS solution overnight. The slides were washed, stained with biotin-coated donkey 
anti-rabbit antibody (Jackson Immunolabs, Bar Harbor, ME) in 1% BSA/PBS, washed, 
then incubated with a streptavidin-Alexa Fluor 488 conjugated antibody (Jackson 
Immunolabs). The slides were washed, then the cells were permeabilized with 0.01% 
Triton X-100 and stained with DAPI. Slides were cover-slipped and imaged.  
 
Immunoblotting 
HASM cells were treated with carbachol (25 µM Cch, 10 min) then with formoterol 
(100 pM, 5 min) ± simultaneous budesonide stimulation (1 µM, 5 min). Cells were then 
treated with 500 M perchloric acid, plates scraped, and cells pelleted. Pellets were 
solubilized in RIPA and sonicated prior to being subjected to SDS PAGE and transferred 
to nitrocellulose membranes, as previously described (18) then assessed for 
phosphorylation of MLC and total MLC. Total GRα and phospho-GRα were assessed in 
cell lysates following siRNA transfection of HASM with non-targeting and GRα-targeted 
siRNA. 
 
Single analyte ELISAs  
HASM transfected with non-targeting or GRα-targeted siRNA were treated with 
budesonide (100 nM, 1 hr) prior to stimulation with TNFα (10 ng/ml, 24 hr).  Single analyte 
ELISAs were utilized to assess release of IL-6, RANTES, and IL-8 into the media.  Each 
condition represents duplicate samples from a single donor, each run in triplicate. 
 
 
Statistical analyses 
Standard curves for cAMP generation were fitted and unknown values 
extrapolated using GraphPad Prism 6.0h (GraphPad Software Inc., San Diego, CA). Data 
are presented as the mean ± SEM. Statistical comparisons (t-tests and one-way analysis 
of variance) were performed and graphics were generated using GraphPad Prism 6.0h 
(GraphPad Software Inc.).  Unpaired non-parametric analyses were used for hPCLS data 
that was not normally distributed to compare conditions.  Paired parametric analysis was 
used for HASM experiments (ELISA, western blots, and cAMP generation). 
 
Results 
 
Budesonide enhances formoterol-induced bronchodilation 
To examine whether a glucocorticoid and a β2 agonist can additively promote 
bronchodilation, human small airways in hPCLS were preconstricted to carbachol and 
then dilated to formoterol in the absence and presence of budesonide, with the 
budesonide being added simultaneously with the formoterol. Budesonide treatment 
augmented formoterol-induced bronchodilation (Figure 1), increasing maximal levels of 
bronchodilation. Similarly, the integrated bronchodilator response as represented by Area 
Under the Curve (AUC) significantly increased. Budesonide alone had little effect on 
luminal diameter dilation despite being administered at similar concentrations as 
formoterol (data not shown). These data show that simultaneous administration of 
budesonide augments β2 agonist-induced dilation of human small airways. 
 
Budesonide amplifies PGE2-, cholera toxin- and forskolin-mediated bronchodilation 
 Given that budesonide augments airway dilation to a β2 agonist, we next examined 
whether budesonide enhances dilation mediated by activation of other GPCRs coupled 
to Gαs or via direct activation of Gαs or adenylyl cyclase. We showed that simultaneous 
administration of budesonide enhances PGE2-induced bronchodilation of airways (Figure 
2), with increases in maximal bronchodilation and AUC to PGE2. To assess whether the 
effect of budesonide was due to activation of Gαs, a G protein shared between the β2AR 
and EP2/4 receptors, we utilized cholera toxin (CTX) to induce bronchodilation in hPCLS. 
Simultaneous administration of budesonide with CTX induced greater maximal 
bronchodilation overall responses to CTX compared to CTX alone (Figure 3). To assess 
whether budesonide enhanced direct adenylyl cyclase (AC)-induced bronchodilation, 
hPCLS were exposed to forskolin (FSK) in the presence or absence of budesonide. 
Simultaneous budesonide administration enhanced FSK-induced bronchodilation (Figure 
4), significantly increasing the AUC to FSK compared to control.  
 
Budesonide enhances formoterol-stimulated cAMP production   
To dissect the molecular pathways by which budesonide augments 
bronchodilation of human airway smooth muscle (HASM), HASM were infected with a 
recombinant BacMam expressing a fluorescent cAMP sensor, cADDis, and cAMP levels 
were measured after exposure to varying concentrations of formoterol. The cADDis 
sensor decreases fluorescence upon binding cAMP, providing real-time assessment of 
intracellular cAMP levels without inclusion of phosphodiesterase (PDE) inhibitors. 
Formoterol decreased cADDis fluorescence within minutes that typically stabilized within 
15-20 min (Figure 5A, inset). To account for the rate and maximal levels of cAMP 
production produced by formoterol, the product of the decay rate (K) and the level at 
steady state (plateau) were plotted for each drug concentration. Using this analysis, 
formoterol increased cAMP levels (Figure 5A). In parallel, formoterol-stimulated cAMP 
was measured in HASM treated with vehicle or 10-6 M budesonide given simultaneously. 
Budesonide shifted the formoterol concentration-response curve 3.9-fold leftward (Figure 
5B. Additionally, budesonide at 1 or 10 µM augmented formoterol-induced cAMP 
production, but that effect was not realized at 100 nM budesonide. The effect of 
budesonide on formoterol-stimulated cAMP production in HASM cells therefore mimicked 
the effect of budesonide on agonist-induced bronchodilation observed in hPCLS. 
 
Budesonide enhances PGE2- and forskolin-stimulated cAMP production  
To determine whether budesonide also enhanced cAMP signaling stimulated by 
PGE2, PGE2-stimulated cAMP production was detected by cADDis in a concentration-
dependent manner (Figure 5C). Inclusion of budesonide (1 µM) shifted the PGE2 curve 
leftward 8.4-fold. We next examined cAMP responses to forskolin (FSK), finding that FSK-
stimulated cAMP production was shifted leftward 8.2-fold by inclusion of 1 µM budesonide 
as compared to vehicle (Figure 5D). These data are consistent with the notion that 
budesonide enhances cAMP production initiated by multiple GPCRs in different signaling 
compartments in HASM cells, and that budesonide-mediated augmentation of these 
responses is receptor-independent.  
 
Budesonide, fluticasone and prednisone enhance directly stimulated cAMP production  
Because budesonide enhanced agonist-induced cAMP signaling, we investigated 
whether budesonide alone stimulated cAMP. Significant decreases in cADDis 
fluorescence was observed within seconds of addition of 1 or 10 µM budesonide (data 
not shown). 10 µM budesonide stimulated cAMP levels that were statistically different 
than vehicle within 2 minutes, while 1 µM induced significant changes within 5 minutes. 
The higher concentration of budesonide stimulated changes in cADDis fluorescence that 
were equivalent to maximal concentrations of forskolin (10 µM) or formoterol (not shown). 
However, cADDis is a readily saturated sensor so high levels of cAMP may not be 
distinguishable (19). We also examined cAMP production by other corticosteroids, finding 
that fluticasone and prednisone (data not shown) stimulated cAMP production. 
Fluticasone was equi-effective as budesonide although greater inter-experimental 
variability was observed while prednisone was less efficacious and less potent.  
 
A membrane-bound form of GR (mGR) is present in HASM cells 
 Since budesonide effects on cAMP generation and bronchodilation were rapid, we 
posited that budesonide activates a membrane-associated receptor. Other laboratories 
have identified a mGR that can evoke immediate steroid effects in other cell types (20-
22). Using cell-surface biotin labeling and immunohistochemistry (Figure 6), we showed 
that HASM express mGRs that fail to translocate to the nucleus from the membrane 
despite stimulation with a glucocorticoid (dexamethasone). As expected, cytosolic GR 
translocated to the nucleus as shown in Figure 6. 
 
Budesonide augments formoterol-induced dephosphorylation of myosin light chain 
 Contractile agonists activate GPCRs that evoke HASM shortening by promoting 
phosphorylation of myosin light chain (pMLC). To determine whether formoterol in the 
absence and presence of budesonide modulates agonist-induced excitation-contraction 
signaling, we examined attenuation of carbachol-induced pMLC by formoterol ± 
budesonide. Formoterol alone (10 pM – 10 nM) induced significant reversal of carbachol-
induced pMLC, and simultaneous administration of budesonide with formoterol (at 100 
pM) further augments formoterol-induced pMLC dephosphorylation (Figure 7). These 
data suggest that glucocorticoids can also augment formoterol effects on pro-contractile 
pathways in HASM cells. 
 
GRα knockdown in HASM cells has little effect on cAMP generation in response to 
budesonide or budesonide + formoterol 
To more directly assess the role of the GR in mediating rapid cAMP responses 
to glucocorticoids, we used siRNA to knock down GRα expression in 
HASM.  Transfection of validated siRNA sequences into HASM led to a nearly complete 
loss of GRα immunoreactivity (detected as a doublet of approximately 94 kDa) as 
compared to cells transfected with a scrambled siRNA (Figure 
8A).  GRα mRNA expression in control HASM was readily detected by quantitative RT-
PCR but was undetectable in cells transfected with GRα siRNA (not shown).  We 
then assessed cAMP levels in HASM following siRNA transfection.  Forskolin-stimulated 
cAMP responses were unaltered by GRα knockdown, implying that loss of GRα did not 
alter AC expression or function (data not shown). Budesonide (1 µM) or formoterol (0.1 
nM) each elicited equivalent cAMP responses in both GRα knockdown and control cells 
(Figure 8B and 8C).  cAMP responses to simultaneous addition of budesonide and 
formoterol were greater than either agent alone, but were similar in both control 
and GR⍺  knockdown conditions (Figure 8D).  Knockdown of GRα was confirmed by 
immunoblot, and showed reversal of budesonide attenuation of TNFα-induced 
inflammatory mediator release (data not shown).  These results suggest that 
GRα expression may not be required for rapid, non-genomic signaling by GC.  
 
 
Discussion 
  
In airway smooth muscle, contractile agonists stimulate Ca2+-dependent signaling 
evoking cell shortening regulated in part through increased [Ca2+]i transients, inhibition of 
sarcoplasmic reticulum Ca2+-ATPase (SERCA), and pMLC inducing actin-myosin cross-
bridge cycling and force generation. Agents that mobilize cAMP and activate protein 
kinase A (PKA) protect against or reverse agonist-induced bronchoconstriction. In 
epithelial cells and neurons, glucocorticoids modulate signaling pathways that promote 
relaxation of HASM. Dexamethasone stimulation of bronchial cells attenuated [Ca2+]i 
currents, which was reversed by SERCA inhibitors, PKA, and activated adenylyl cyclase 
(AC) within minutes (20). Further, corticosterone treatment reversed ATP-induced [Ca2+]i 
transients in mouse HT4 neuroblastoma cells (23). In primary HASM cells, budesonide 
stimulation alone increased cAMP levels (data not shown). Interestingly, we show that 
simultaneous budesonide and formoterol significantly reduced carbachol-induced pMLC 
(Figure 7), but little effect of budesonide alone. Others noted existence of a mGR that 
may mediate non-genomic, rapid effects of glucocorticoids. We demonstrate presence of 
mGR in HASM (Figure 6) that does not translocate upon glucocorticoid stimulation. Our 
work suggests that expression of GRα is not necessary to elicit cAMP production in 
response to budesonide or budesonide + formoterol (Figure 8). There is a possibility that 
residual GR protein whose expression was not attenuated by siRNA transfection may 
mediate the effect, but the existence of a modified GR that may not be subject to 
knockdown of the protein may mediate the effects of steroids on cAMP 
production/augmentation of bronchodilation.  Overall, these data suggest that despite the 
effect of glucocorticoids on attenuation of Ca2+-dependent pathways, glucocorticoids 
alone had little effect on agonist-induced bronchoconstriction of small airways (data not 
shown) in hPCLS but rather, amplified β2 agonist-induced bronchodilation. 
Although glucocorticoids alone induced cAMP production (data not shown), these 
steroids had little effect on bronchodilation of small airways in hPCLS (data not shown). 
Robust and sensitive assessment of cAMP pools is achieved using the cADDis reporter 
(19). Although the assay shows increases in cAMP production to budesonide alone, this 
increase in cAMP levels may be insufficient for promoting bronchodilation due to an 
inadequate magnitude or localization of the cAMP signal despite utilizing the same 
concentrations of budesonide as formoterol in the hPCLS bronchodilation assays (10-12 
– 10-5 M, data not shown). Glucocorticoids may therefore be increasing cAMP levels via 
direct activation of Gαs, activation of an unidentified GPCR, or inhibition of 
phosphodiesterases. Others suggest that increases in intracellular cAMP elicited by 
glucocorticoids may be due to inhibition of ABCC4, an ATP binding cassette transporter 
that pumps cAMP into the extracellular space.  In differentiated airway epithelial cells, 
dexamethasone, but not budesonide, augmented activity of GRE-luciferase when given 
with forskolin treatment.  Additionally, blockade of ABCC4 potentiated activity of the GRE-
luciferase in the presence of either dexamethasone or budesonide treatment (24).  Unlike 
airway epithelial cells, β2 agonist or forskolin treatment had little effect on extracellular 
levels of cAMP in HASM (data not shown).  However, we reported that ABCC4 is 
expressed in HASM cells, and its expression is augmented by budesonide treatment (25).  
In the aforementioned studies, glucocorticoid treatment was for 6-12 hours, conceivably 
the mechanisms modulating rapid glucocorticoid stimulation may differ.  Future studies 
will address whether non-genomic effects of glucocorticoids are mediated by activation 
of ABCC4 proteins. 
Others noted acute glucocorticoid stimulation activates signaling pathway 
components in non-muscle cells that are associated with bronchodilatory responses in 
smooth muscle. In bronchial epithelial cells dexamethasone inhibited agonist-induced 
[Ca2+]i, with the inhibition sensitive to AC and PKA inhibition (20). Other show a non-
genomic glucocorticoid effect that was PKA-dependent in a neural cell line (23). 
Accordingly, to assess mechanisms by which steroid may be augmenting agonist-induced 
bronchodilation we examined the effect of glucocorticoids on: (1) selectivity of responses 
we observed to the β2AR; (2) direct activation of Gαs; and (3) whether the response 
observed was receptor-dependent. We found that PGE2-, CTX-, and FSK-stimulated 
bronchodilation of small airways (Figures 2, 3 and 4, respectively) was augmented by co-
administration of budesonide. Similarly, PGE2-, and FSK-induced cAMP production in 
HASM (Figure 5C and D) was augmented by budesonide co-administration. Despite the 
cADDis characterizing budesonide’s effects on CTX-induced cAMP production, CTX 
induced such saturating levels of cAMP production in HASM cells making us unable to 
detect a synergism above CTX stimulation alone (data not shown).  
 Interestingly, synergism between glucocorticoids and β2 agoinsts has been 
examined previously.  A recent study noted that beclomethasone augmented formoterol-
induced reversal of pre-contracted airways (26), to about ~30% maximally (27).  Although 
there was synergism between the two therapeutics, the beclomethasone dose was given 
overnight, with effects likely genomic.  This is in direct contrast to what our studies show, 
where despite budesonide inducing cAMP production in HASM, it alone was unable to 
induce bronchodilation even at a concentration of 100 µM.  Additionally, the 2016 study 
utilized non-selective inhibitors of PKA and Gαs to establish roles for those protein in 
beclomethasone-induced bronchodilation in lung slices.  Our studies have the advantage 
of observing cAMP production in live primary HASM in real time, a system in which we 
can genetically manipulate components of signaling pathways to more rigorously 
ascertain the necessity and sufficiency specific molecules in the responses we observe. 
 Our studies identify mechanisms by which budesonide, a potent glucocorticoid, 
rapidly activates cAMP production and augments agonist-mediated bronchodilation. This 
is the first direct demonstration that glucocorticoids stimulate cAMP production in airway 
smooth muscle. These mechanisms may explain, in part, how combination therapy of β2 
agonists and ICS offer greater efficacy in comparison to either drug alone.  Interestingly, 
these beneficial effects occur separate and distinct from any anti-inflammatory effects 
(11).  Combination therapy represents a cornerstone for maintenance therapy in asthma 
and COPD. Evidence also suggests that this combination can serve as an anti-
inflammatory reliever therapy (when added to maintenance) that decreases exacerbation 
rates, improves asthma symptoms, and enhances lung function as compared to higher 
doses of inhaled corticosteroids (ICS) alone (4-6). Our data identify molecular 
mechanisms by which steroids and long-acting β2 agonists together improve 
bronchodilation. 
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Figure 1 – Acute budesonide stimulation augments formoterol-induced 
bronchodilation, but does not induce bronchodilation alone. (A) Simultaneous 
stimulation of hPCLS with budesonide (10-5 M) with formoterol (10-12 – 10-6 M) augments 
(B) maximal bronchodilation (formoterol vs. budesonide at 10-6 M formoterol, 71.4 ± 5% 
vs. 89.7 ± 7.3%), and increases the integrated (C) area under the curve vs. formoterol 
alone (formoterol vs. formoterol + budesonide, 156.8 ± 25.9 vs. 257.1 ± 51.6). Data 
represents n=15-25 donors, p<0.05 vs formoterol alone. (D) Budesonide alone does not 
induce bronchodilation in hPCLS. Data represents 2 (budesonide alone) - 15 (formoterol) 
donors, 6-36 slices/condition. 
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Figure 2 – Simultaneous budesonide treatment augments PGE2-induced 
bronchodilation of human small airways. Budesonide (10 µM) was given 
simultaneously with PGE2 (10-10 – 10-5 M) and bronchodilation was assessed. 
Concentration-response curves (A) are represented as % dilation for the combination 
compared to PGE2-induced dilation alone. Maximal bronchodilation at 10-5 M PGE2 (B, 
PGE2 vs. PGE2 + budesonide at a maximum of 10-5 M PGE2, 116.6 ± 16.6% vs. 283.3 ± 
37.3%) and integrated area under the curve (C, PGE2 vs. PGE2 + budesonide, 264.5 ± 
40 vs. 736.2 ± 209.6) of PGE2-induced bronchodilation were significantly increased. Data 
represents n=3 donors, *p<0.05 compared to PGE2 stimulation alone. 
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Figure 3 – Budesonide significantly augments cholera toxin-induced 
bronchodilation of human small airways. Budesonide (10 µM) was given 
simultaneously with cholera toxin (CTX, 0.01-100 µg/ml) and bronchodilation was 
assessed. Concentration-response curves (A) were normalized to CTX stimulation alone 
set to 100%. Maximum bronchodilation at 100 µg/mL (B, CTX vs. CTX + budesonide at a 
maximum of 100 µg/ml CTX, 105.5 ± 3.9% vs. 128.4 ± 17.5%) and area under the curve 
(C, (CTX vs. CTX + budesonide, 200.8 ± 13.8 vs. 361.5 ± 112.6) were significantly 
increased with budesonide stimulation. Data are representative of n=5 donors, 11-13 
slices/condition, *p<0.05 compared to CTX stimulation alone. 
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Figure 4 – Budesonide augments forskolin-induced bronchodilation of human 
small airways. Budesonide (10 µM) was given simultaneously with forskolin (Fsk, 10-12 
– 10-5 M) and bronchodilation was assessed. Concentration-response curves to Fsk (A) 
were plotted.  Maximal bronchodilation at 10-5 M FSK (B, FSK vs. FSK + budesonide at 
maximum of 10-5 M FSK, 83.7 ± 8.5% vs. 110.1 ± 10.6%) and area under the curve (C, 
FSK vs. FSK + budesonide, 151.9 ± 11.8 vs. 232.3 ± 29.1) were significantly increased 
in the presence of budesonide. Data are representative of n=5 donors, * p<0.05 compared 
to control/Fsk. 
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Figure 5 – Budesonide alone induces cAMP production in HASM cells, and 
enhances formoterol, PGE2, and forskolin-induced cAMP production. HASM cells 
were incubated with recombinant BacMam virus expressing the cADDis cAMP sensor for 
24 hr. After establishing baseline, fluorescence decay was monitored for 30 min after 
addition of drug. (A) cADDis sensor fluorescent decay curves elicited by various 
concentrations of formoterol were fit by one-phase decay non-linear regression analysis 
(inset, 10-12 – 10-6 M formoterol, log EC50 of -7.78 ± 0.185). The rate (K) was multiplied 
by the steady state change in fluorescence (plateau) for each concentration of formoterol. 
Each point represents the mean ± SEM of n=5. (B) Budesonide alone (1 or 10 µM) elicits 
cAMP production in cells, and is compared to forskolin (10 µM) stimulation.  Each point 
represents the mean ± SEM of n=4-6 cell lines and lines represent the fit by one-phase 
decay non-linear regression analysis. * denotes p < 0.05, ** denotes p < 0.01 of each time 
point compared to vehicle using multiple t tests and the Holm-Sidak method for correction 
of multiple comparisons. (C) Formoterol concentration-responses curves in the presence 
of vehicle or 1 µM budesonide. Each point represents the mean ± SEM of n=5 cell lines 
(log EC50 formoterol vs. formoterol + budesonide, -7.76 ± 0.205 vs. -8.36 ± 0.189, 
p=0.021). (D) PGE2 concentration-responses curves in the presence of vehicle or 1 µM 
budesonide. Each point represents the mean ± SEM of n=4 cell lines (log EC50 PGE2 vs. 
PGE2 + budesonide, -7.85 ± 0.062 vs. -8.78 ± 0.129, p=0.046). (E) Forskolin 
concentration-responses curves in the presence of vehicle or 1 µM budesonide. Each 
point represents the mean ± SEM of n=7 cell lines (log EC50 FSK vs. FSK + budesonide, 
-6.75 ± 0.168 vs. -7.67 ± 0.190, p=0.005). 
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Figure 6 - mGR exists in HASM. (A) HASM from non-diseased lung donors was 
biotinylated and purification of a membrane fraction determined the existence of a 
membrane bound form of the glucocorticoid receptor. Presence of the epidermal growth 
factor receptor (EGFR) and absence of GAPDH and COX IV (cytosolic proteins) were 
used as controls for purity of membrane protein isolation. (B) HASM cells were fixed with 
acetone following stimulation for 30 min with dexamethasone (1 µM). Fixed cells were 
then probed for glucocorticoid receptor and DAPI. Data are representative of 3 separate 
non-asthma donors for both (A) and (B). 
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Figure 7 – Budesonide augments formoterol-mediated attenuation of carbachol 
(Cch)-induced phosphorylation of myosin light chain. HASM cells were treated with 
Cch (25 µM, 15 min), then treated simultaneously with formoterol (10 pM – 10 nM, 5 min) 
and budesonide (1 µM, 5 min). Phosphorylation of myosin light chain was assessed by 
immunoblot, using total myosin light chain as a loading control (A). Data are expressed 
as fold compared to control (B), and are representative of 5 separate HASM donors (* 
p<0.05). 
 
 
 
Figure 8 – Knockdown of GRα had little effect on budesonide or budesonide + 
formoterol-induced cAMP production in HASM.  HASM were transfected with siRNA 
specific for GRαor scrambled control (mock) for 72 hr. A:  Lysates were collected and 
analyzed by immunoblotting using antibodies specific for GRα or β-actin. Each lane 
shows one of 3 separate experiments on individual cell lines.  B, C and D: cADDis sensor 
was expressed in HASM with a recombinant BacMam virus then cAMP responses to 
budesonide (1 µM, B), formoterol (0.1 nM, C) or both budesonide and formoterol (1 µM 
and 0.1 nM, respectively, D) were measured in HASM were transfected with non-
targeting siRNA or siRNA specific for GRα. Each point represents the mean ± SEM of 
n=4-5 cell lines. 
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